ORNITHINE
Gastrointestinal Bleeding
Hospital Universitari Vall d'Hebron Research InstituteSmall moleculePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Gastrointestinal Bleeding cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PROPRANOLOL West China Hospital | Phase 4 | BBB |
NORMAL HUMAN SERUM ALBUMIN King George's Medical University | Phase 4 | BB |
CARVEDILOL West China Hospital | Phase 4 | BB |
PHYTONADIONE, (E)-(±)- Tanta University | Phase 4 | BB |
NADOLOL National Science and Technology Council, Taiwan | Phase 4 | BB |
View all 15 →
Same molecule, other indications
ORNITHINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →